Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient
Abstract
The COVID-19 pandemic has had unprecedented health and economic impact, but currently there are no approved therapies. We have isolated an antibody, EY6A, from a late-stage COVID-19 patient and show it neutralises SARS-CoV-2 and cross-reacts with SARS-CoV-1. EY6A Fab binds tightly (KD of 2 nM) the receptor binding domain (RBD) of the viral Spike glycoprotein and a 2.6Å crystal structure of an RBD/EY6A Fab complex identifies the highly conserved epitope, away from the ACE2 receptor binding site. Residues of this epitope are key to stabilising the pre-fusion Spike. Cryo-EM analyses of the pre-fusion Spike incubated with EY6A Fab reveal a complex of the intact trimer with three Fabs bound and two further multimeric forms comprising destabilized Spike attached to Fab. EY6A binds what is probably a major neutralising epitope, making it a candidate therapeutic for COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (11725)
- Bioengineering (8728)
- Bioinformatics (29135)
- Biophysics (14940)
- Cancer Biology (12052)
- Cell Biology (17363)
- Clinical Trials (138)
- Developmental Biology (9408)
- Ecology (14147)
- Epidemiology (2067)
- Evolutionary Biology (18272)
- Genetics (12223)
- Genomics (16773)
- Immunology (11844)
- Microbiology (28027)
- Molecular Biology (11564)
- Neuroscience (60841)
- Paleontology (451)
- Pathology (1864)
- Pharmacology and Toxicology (3232)
- Physiology (4940)
- Plant Biology (10405)
- Synthetic Biology (2878)
- Systems Biology (7335)
- Zoology (1642)